ALAMEDA, Calif. (AP) _ Exelixis Inc. (EXEL) on Thursday reported a third-quarter loss of $32 million, after reporting a profit in the same period a year earlier.

On a per-share basis, the Alameda, California-based company said it had a loss of 10 cents.

The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 5 cents per share.

The drug developer posted revenue of $231.1 million in the period, exceeding Street forecasts. Five analysts surveyed by Zacks expected $215.9 million.

Exelixis expects full-year revenue in the range of $900 million to $950 million.

Exelixis shares have climbed 26% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $22.16, an increase of 41% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EXEL at https://www.zacks.com/ap/EXEL

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News